Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 2 boards, counting each seat separately. Longest: Lineage Cell Therapeutics Inc., 3 years.
Lineage Cell Therapeutics Inc.
Director
STAAR Surgical Company
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 10, 2026 | Insight Molecular Diagnostics Inc. | Open-market purchase | +521,739 | $5.75 | $2,999,999 |
| Feb 10, 2026 | Insight Molecular Diagnostics Inc. | Open-market purchase | +0 | — | — |
| Jan 9, 2026 | STAAR Surgical Company | Open-market purchase | +27,485 | $22.05 | $606,044 |
| Jan 9, 2026 | STAAR Surgical Company | Open-market purchase | +0 | — | — |
| Jan 8, 2026 | STAAR Surgical Company | Open-market purchase | +3,240 | $21.94 | $71,086 |
| Jan 8, 2026 | STAAR Surgical Company | Open-market purchase | +0 | — | — |
| Jan 7, 2026 | STAAR Surgical Company | Open-market purchase | +66,467 | $22.00 | $1,462,274 |
| Jan 7, 2026 | STAAR Surgical Company | Open-market purchase | +0 | — | — |
| Jan 6, 2026 | STAAR Surgical Company | Open-market purchase | +186,946 | $21.01 | $3,927,735 |
| Jan 6, 2026 | STAAR Surgical Company | Open-market purchase | +0 | — | — |
| Jan 6, 2026 | STAAR Surgical Company | Open-market purchase | +150,000 | $22.38 | $3,357,000 |
| Jan 6, 2026 | STAAR Surgical Company | Open-market purchase | +0 | — | — |
| Nov 21, 2025 | STAAR Surgical Company | Open-market purchase | +797,486 | $27.86 | $22,217,960 |
| Nov 21, 2025 | STAAR Surgical Company | Open-market purchase | +0 | — | — |
| Nov 20, 2025 | STAAR Surgical Company | Open-market purchase | +393,382 | $27.14 | $10,676,387 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.